GlassScriptPhysician profile
Roopashree Prabhushankar
NPI 1831402429
$3,054.73
in general payments reported to CMS, 2019-2025
25 companies · $415 in 2025
The $415 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $110 · 2021: $258 · 2022: $321 · 2023: $666 · 2024: $384 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359 · Gift: $59.40 · Education: $46.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.40 |
| Gift | $59.40 |
| Education | $46.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $678.51 | 2019-2024 | Farxiga |
| Corcept Therapeutics | $419.49 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.33 | 2019-2024 | Jardiance |
| Mannkind Corporation | $256.69 | 2019-2024 | Afrezza |
| Xeris Pharmaceuticals, INC. | $158.98 | 2022-2024 | Recorlev, Gvoke Hypopen |
| Abbott Laboratories | $158.94 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $151.65 | 2023-2025 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $127.94 | 2025 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Novo Nordisk INC | $110.58 | 2024-2025 | Wegovy |
| Lilly USA, LLC | $106.19 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $63.01 | 2019-2023 | |
| Shire North American Group INC | $42.60 | 2019 | |
| Opko Pharmaceuticals, LLC | $42.14 | 2019-2024 | Rayaldee |
| Recordati_rare_diseases_inc. | $41.12 | 2023-2024 | Isturisa, Signifor Lar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39.30 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $39.18 | 2023 | Nexletol, Contrave, Nexlizet |
| Ascendis Pharma Endocrinology INC | $27.70 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $20.45 | 2023 | Jynarque |
| Calliditas Therapeutics US INC. | $17.68 | 2022 | |
| Amgen INC. | $15.63 | 2024 | Krystexxa |
| Medtronic, INC. | $15.47 | 2023 | Inpen Smart Insulin Delivery System |
| Arbor Pharmaceuticals, INC. | $15.41 | 2021 | |
| Strongbridge US INC. | $14.09 | 2019 | |
| Cequr Corporation | $12.65 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopashree Prabhushankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.